BRCA 1 sequence analysis in women at high risk for susceptibility mutations - Risk factor analysis and implications for genetic testing

被引:308
作者
ShattuckEidens, D
Oliphant, A
McClure, M
McBride, C
Gupte, J
Rubano, T
Pruss, D
Tavtigian, SV
Teng, DHF
Adey, N
Staebell, M
Gumpper, K
Lundstrom, R
Hulick, M
Kelly, M
Holmen, J
Lingenfelter, B
Manley, S
Fujimura, F
Luce, M
Ward, B
CannonAlbright, L
Steele, L
Offit, K
Gilewski, T
Norton, L
Brown, K
Schulz, C
Hampel, H
Schluger, A
Giulotto, E
Zoli, W
Ravaioli, A
Nevanlinna, H
Pyrhonen, S
Rowley, P
Loader, S
Osborne, MP
Daly, M
Tepler, I
Weinstein, PL
Scalia, JL
Michaelson, R
Scott, RJ
Radice, P
Pierotti, MA
Garber, JE
Isaacs, C
Peshkin, B
Lippman, ME
机构
[1] MYRIAD GENET INC, SALT LAKE CITY, UT 84108 USA
[2] MYRIAD GENET LABS INC, SALT LAKE CITY, UT USA
[3] UNIV UTAH, DEPT MED INFORMAT, SALT LAKE CITY, UT 84112 USA
[4] MEM SLOAN KETTERING CANC CTR, NEW YORK, NY USA
[5] UNIV PAVIA, DEPT GENET & MICROBIOL, I-27100 PAVIA, ITALY
[6] OSPED GB MORGAGNI L PIERANTONE, DEPT MED ONCOL, FORLI, ITALY
[7] IST ONCOL ROMAGNOLO, FORLI, ITALY
[8] OSPED INFERMI RIMINI, DEPT ONCOL, RIMINI, ITALY
[9] UNIV HELSINKI, CENT HOSP, DEPT OBSTET & GYNECOL, FIN-00290 HELSINKI, FINLAND
[10] UNIV HELSINKI, CENT HOSP, DEPT ONCOL, HELSINKI, FINLAND
[11] UNIV ROCHESTER, ROCHESTER, NY USA
[12] STRANG CANC PREVENT CTR, NEW YORK, NY USA
[13] FOX CHASE CANC CTR, PHILADELPHIA, PA 19111 USA
[14] BENNETT CANC CTR, STAMFORD, CT USA
[15] CANC CTR ST BARNABAS, LIVINGSTON, NJ USA
[16] KANTONSSPITAL, DEPT FORSCH, CH-4031 BASEL, SWITZERLAND
[17] IST NAZL STUDIO & CURA TUMORI, I-20133 MILAN, ITALY
[18] DANA FARBER CANC INST, BOSTON, MA 02115 USA
[19] GEORGETOWN UNIV, MED CTR, LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA
[20] N SHORE HEMATOL ONCOL ASSOCIATES PC, SETAUKET, NY USA
[21] IST ANAT PATOL, PISA, ITALY
[22] UNIV CONNECTICUT, HLTH SCI CTR, DIV HUMAN GENET, FARMINGTON, CT USA
[23] UNIV PENN, DEPT MED, PHILADELPHIA, PA 19104 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1997年 / 278卷 / 15期
关键词
D O I
10.1001/jama.278.15.1242
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-A mutation in the BRCA1 gene may confer substantial risk for breast and/or ovarian cancer, However, knowledge regarding all possible mutations and the relationship between risk factors and mutations is incomplete. Objectives.-To identify BRCA1 mutations and to determine factors that best predict presence of a deleterious BRCA1 mutation in patients with breast and/or ovarian cancer. Design.-A complete sequence analysis of the BRCA1 coding sequence and flanking intronic regions was performed in 798 women in a collaborative effort involving institutions from the United States, Italy, Germany, Finland, and Switzerland. Participants.-Institutions selected 798 persons representing families (1 person for each family) thought to be at elevated a priori risk of BRCA1 mutation due to potential risk factors, such as multiple cases of breast cancer, early age of breast cancer diagnosis, and cases of ovarian cancer, No participant was from a family in which genetic markers showed linkage to the BRCA1 locus. Major Outcome Measures.-Sequence variants detected in this sample are presented along with analyses designed to determine predictive characteristics of those testing positive for BRCA1 mutations. Results.-In 102 women (12.8%), clearly deleterious mutations were detected. Fifty new genetic alterations were found including 24 deleterious mutations, 24 variants of unknown significance, and 2 rare polymorphisms. In a subset of 71 Ashkenazi Jewish women, only 2 distinct deleterious mutations were found: 185delAG in 17 cases and 5382insC in 7 cases. A bias in prior reports for mutations in exon 11 was revealed, Characteristics of a patient's specific diagnosis (unilateral or bilateral breast cancer, with or without ovarian cancer), early age at diagnosis, Ashkenazi Jewish ethnicity, and family history of cancer were positively associated with the probability of her carrying a deleterious BRCA1 mutation. Conclusions.-Using logistic regression analysis, we provide a method for evaluating the probability of a woman's carrying a deleterious BRCA1 mutation for a wide range of cases, which can be an important tool for clinicians as they incorporate genetic susceptibility testing into their medical practice.
引用
收藏
页码:1242 / 1250
页数:9
相关论文
共 30 条
  • [1] *AM CANC SOC, 1997, CANC FACTS FIG 1997
  • [2] The BRCA1 and 1A1.3B promoters are parallel elements of a genomic duplication at 17q21
    Barker, DF
    Liu, XD
    Almeida, ERA
    [J]. GENOMICS, 1996, 38 (02) : 215 - 222
  • [3] Barker DF, 1996, GENET EPIDEMIOL, V13, P595
  • [4] A SUGGESTED NOMENCLATURE FOR DESIGNATING MUTATIONS
    BEAUDET, AL
    TSUI, LC
    [J]. HUMAN MUTATION, 1993, 2 (04) : 245 - 248
  • [5] Berman DB, 1996, AM J HUM GENET, V58, P1166
  • [6] Brown MA, 1996, ONCOGENE, V12, P2507
  • [7] The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor
    Chen, CF
    Li, S
    Chen, YM
    Chen, PL
    Sharp, ZD
    Lee, WH
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (51) : 32863 - 32868
  • [8] Claus EB, 1996, CANCER, V77, P2318, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2318::AID-CNCR21>3.0.CO
  • [9] 2-Z
  • [10] COHEN MM, 1994, AM J HUM GENET, V55, pR1